The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis

Emily Rimmer, Brett L Houston, Anand Kumar, Ahmed M Abou-Setta, Carol Friesen, John C Marshall, Gail Rock, Alexis F Turgeon, Deborah J Cook, Donald S Houston, Ryan Zarychanski, Emily Rimmer, Brett L Houston, Anand Kumar, Ahmed M Abou-Setta, Carol Friesen, John C Marshall, Gail Rock, Alexis F Turgeon, Deborah J Cook, Donald S Houston, Ryan Zarychanski

Abstract

Introduction: Sepsis and septic shock are leading causes of intensive care unit (ICU) mortality. They are characterized by excessive inflammation, upregulation of procoagulant proteins and depletion of natural anticoagulants. Plasma exchange has the potential to improve survival in sepsis by removing inflammatory cytokines and restoring deficient plasma proteins. The objective of this study is to evaluate the efficacy and safety of plasma exchange in patients with sepsis.

Methods: We searched MEDLINE, EMBASE, CENTRAL, Scopus, reference lists of relevant articles, and grey literature for relevant citations. We included randomized controlled trials comparing plasma exchange or plasma filtration with usual care in critically ill patients with sepsis or septic shock. Two reviewers independently identified trials, extracted trial-level data and performed risk of bias assessments using the Cochrane Risk of Bias tool. The primary outcome was all-cause mortality reported at longest follow-up. Meta-analysis was performed using a random-effects model.

Results: Of 1,957 records identified, we included four unique trials enrolling a total of 194 patients (one enrolling adults only, two enrolling children only, one enrolling adults and children). The mean age of adult patients ranged from 38 to 53 years (n = 128) and the mean age of children ranged from 0.9 to 18 years (n = 66). All trials were at unclear to high risk of bias. The use of plasma exchange was not associated with a significant reduction in all-cause mortality (risk ratio (RR) 0.83, 95% confidence interval (CI) 0.45 to 1.52, I(2) 60%). In adults, plasma exchange was associated with reduced mortality (RR 0.63, 95% CI 0.42 to 0.96; I(2) 0%), but was not in children (RR 0.96, 95% CI 0.28 to 3.38; I(2) 60%). None of the trials reported ICU or hospital lengths of stay. Only one trial reported adverse events associated with plasma exchange including six episodes of hypotension and one allergic reaction to fresh frozen plasma.

Conclusions: Insufficient evidence exists to recommend plasma exchange as an adjunctive therapy for patients with sepsis or septic shock. Rigorous randomized controlled trials evaluating clinically relevant patient-centered outcomes are required to evaluate the impact of plasma exchange in this condition.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-analysis study flow diagram.
Figure 2
Figure 2
Mortality associated with plasma exchange. Boxes and horizontal lines represent point estimates, varying in size according to the weight in the analysis, and 95% confidence intervals. Chi2 = Chi-squared; df = degrees of freedom; CI = Confidence interval; I2 = I-squared; M-H = Mantel-Haenszel; P = P value; RR = risk ratio; Tau2 = Tau-squared; Z = Z score.

References

    1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–851. doi: 10.1056/NEJMra1208623.
    1. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units. JAMA. 1995;274:968. doi: 10.1001/jama.1995.03530120060042.
    1. Schoenberg MH, Weiss M, Radermacher P. Outcome of patients with sepsis and septic shock after ICU treatment. Langenbecks Arch Surg. 1998;383:44–48. doi: 10.1007/s004230050090.
    1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–1554. doi: 10.1056/NEJMoa022139.
    1. Fortenberry JD, Paden ML. Extracorporeal therapies in the treatment of sepsis: experience and promise. Semin Pediatr Infect Dis. 2006;17:72–79. doi: 10.1053/j.spid.2006.04.005.
    1. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH. Apheresis Applications Committee of the American Society for A: Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25:83–177. doi: 10.1002/jca.20240.
    1. Stegmayr B. Apheresis in patients with severe sepsis and multi organ dysfunction syndrome. Transfus Apher Sci. 2008;38:203–208. doi: 10.1016/j.transci.2008.03.009.
    1. Vain NE, Mazlumian JR, Swarner OW, Cha CC. Role of exchange transfusion in the treatment of severe septicemia. Pediatrics. 1980;66:693–697.
    1. Bjorvatn B, Bjertnaes L, Fadnes HO, Flaegstad T, Gutteberg TJ, Kristiansen BE, Pape J, Rekvig OP, Osterud B, Aanderud L. Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. Br Med J. 1984;288:439–441. doi: 10.1136/bmj.288.6415.439.
    1. Brandtzaeg P, Sirnes K, Folsland B. Plasmapheresis in the treatment of severe meningococcal or pneumococcal septicaemia with DIC and fibrinolysis. Preliminary data on eight patients. Scand J Clin Lab Invest. 1985;45:53–55.
    1. Drapkin MS, Wisch JS, Gelfand JA, Cannon JG, Dinarello CA. Plasmapheresis for fulminant meningococcemia. Pediatr Infect Dis J. 1989;8:399–400. doi: 10.1097/00006454-198906000-00015.
    1. Scharfman WB, Tillotson JR, Taft EG, Wright E. Plasmapheresis for meningococcemia with disseminated intravascular coagulation. N Engl J Med. 1979;300:1277–1278.
    1. Schmidt J, Mann S, Mohr VD, Lampert R, Firla U, Zirngibl H. Plasmapheresis combined with continuous venovenous hemofiltration in surgical patients with sepsis. Intensive Care Med. 2000;26:532–537. doi: 10.1007/s001340051200.
    1. Van Deuren M, Santman FW, Van Dalen R, Sauerwein RW, Span LFR, Van der Meer JWM. Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis. 1992;15:424–430. doi: 10.1093/clind/15.3.424.
    1. Gardlund B, Sjolin J, Nilsson A, Roll M, Wickerts CJ, Wikstrom B, Wretlind B. Plasmapheresis in the treatment of primary septic shock in humans. Scand J Infect Dis. 1993;25:757–761. doi: 10.3109/00365549309008575.
    1. Stegmayr BG. Plasma exchange in patients with septic shock including acute renal failure. Blood Purif. 1996;14:102–108. doi: 10.1159/000170251.
    1. Chandler J, Churchill R, Higgins J, Lasserson T, Tovey D: Methodological Expectations of Cochrane Intervention Reviews (MECIR) methodological standards for the conduct of new Cochrane Intervention Reviews, Version 2.1. The Cochrane Collaboration; 2011. []
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535.
    1. Higgins JP, Green S (Eds): Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 edition. The Cochrance Collaboration; 2011. []
    1. Higgins JPT, Green S (Eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration; 2008. []
    1. Julian PTH, Douglas GA, Peter CG, Peter JÃ, David M, Andrew DO, Jelena S, Kenneth FS, Laura W, Jonathan ACS. The Cochrane Collaboration™ tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.
    1. Knaus WA, Draper EA. APACHE II: A severity of disease classification system. Crit Care Med. 1985;13:818–829. doi: 10.1097/00003246-198510000-00009.
    1. Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, Presneill JJ. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med. 1999;27:2096–2104. doi: 10.1097/00003246-199910000-00003.
    1. Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med. 2002;28:1434–1439. doi: 10.1007/s00134-002-1410-7.
    1. Nguyen TC, Han YY, Kiss JE, Hall MW, Hassett AC, Jaffe R, Orr RA, Janosky J, Carcillo JA. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med. 2008;36:2878–2887. doi: 10.1097/CCM.0b013e318186aa49.
    1. Long EJ, Shann F, Pearson G, Buckley D, Butt W. A randomised controlled trial of plasma filtration in severe paediatric sepsis. Crit Care Resusc. 2013;15:198–204.
    1. Aird WC. The hematologic system as a marker of organ dysfunction in sepsis. Mayo Clin Proc. 2003;78:869–881. doi: 10.4065/78.7.869.
    1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent J-L, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250–1256. doi: 10.1097/01.CCM.0000050454.01978.3B.
    1. Matthay MA. Severe sepsis – a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med. 2001;344:759–762. doi: 10.1056/NEJM200103083441009.
    1. Levi M, Schultz M, van der Poll T. Coagulation biomarkers in critically ill patients. Crit Care Clin. 2011;27:281–297. doi: 10.1016/j.ccc.2010.12.009.
    1. Toltl LJ, Swystun LL, Pepler L, Liaw PC. Protective effects of activated protein C in sepsis. Thromb Haemost. 2008;100:582–592.
    1. Afshari A, Wetterslev J, Brok J, Moller A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ. 2007;335:1248–1251. doi: 10.1136/bmj.39398.682500.25.
    1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. doi: 10.1056/NEJM200103083441001.
    1. Esmon CT. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood. 2000;95:1113–1116.
    1. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA, Optimus Trial Study Group Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238–247. doi: 10.1001/jama.290.2.238.
    1. Fisher CJ, Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC, Phase III, rhIL-1ra Sepsis Syndrome Study Group Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994;271:1836–1843. doi: 10.1001/jama.1994.03510470040032.
    1. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, Quenzer RW, Iberti TJ, Macintyre N, Schein RM. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med. 1995;23:994–1006. doi: 10.1097/00003246-199506000-00003.
    1. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med. 1996;24:1431–1440. doi: 10.1097/00003246-199609000-00002.
    1. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC, TNG-alpha MAb Sepsis Study Group Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995;273:934–941. doi: 10.1001/jama.1995.03520360048038.
    1. Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, Cardona X, Inguaggiato P, Pilotto L, D’Intini V, Bellomo R. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003;27:792–801. doi: 10.1046/j.1525-1594.2003.07289.x.
    1. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393–397. doi: 10.1056/NEJM199108083250604.
    1. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit Care Med. 2009;37:291–304. doi: 10.1097/CCM.0b013e31819267fb.
    1. Zhou F, Peng Z, Murugan R, Kellum JA. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med. 2013;41:2209–2220. doi: 10.1097/CCM.0b013e31828cf412.
    1. Livigni S, Bertolini G, Rossi C, Ferrari F, Giardino M, Pozzato M, Remuzzi G, GiViTI (Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva) Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial. BMJ Open. 2014;4:e003536. doi: 10.1136/bmjopen-2013-003536.
    1. Taori G, Ho KM, George C, Bellomo R, Webb SA, Hart GK, Bailey MJ. Landmark survival as an end-point for trials in critically ill patients – comparison of alternative durations of follow-up: an exploratory analysis. Crit Care. 2009;13:R128. doi: 10.1186/cc7988.
    1. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003;348:1123–1133. doi: 10.1056/NEJMra011883.
    1. Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial. 2005;9:391–395. doi: 10.1111/j.1744-9987.2005.00319.x.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj